Trovò M G, Minatel E, Veronesi A, Roncadin M, De Paoli A, Franchin G, Magri D M, Tirelli U, Carbone A, Grigoletto E
Radiotherapy Department, Centro di Riferimento Oncologico, Aviano, Italy.
Cancer. 1990 Feb 1;65(3):400-4. doi: 10.1002/1097-0142(19900201)65:3<400::aid-cncr2820650304>3.0.co;2-h.
Between June 1980 and December 1983, 111 patients with inoperable epidermoid bronchogenic carcinoma (limited disease) were entered into a randomized trial comparing radiotherapy alone versus radiotherapy and combination chemotherapy with cyclophosphamide, Adriamycin (doxorubicin), methotrexate, and procarbazine. Thirty-five of 62 (56.4%) patients treated with 4500 rad in 15 fractions in 3 weeks and 19 of 49 (38.8%) patients treated with the same radiation treatment and chemotherapy had an objective response. The difference in response rate was not significant (P = 0.900). Median time to progression was 5.9 and 7.02 months, respectively, for the radiation treatment and the combined treatment. Median survival was 11.74 and 10.03 months, respectively, without statistically significant differences between the two groups of patients. The toxicity was acceptable and no treatment-related death occurred in either treatment schedule. In this study no significant superiority of combined radiotherapy and chemotherapy treatment over radiation therapy alone was evidenced. Whether different chemotherapy regimens may prove more effective in this context should be clarified by further studies.
1980年6月至1983年12月期间，111例无法手术的表皮样支气管癌（局限性疾病）患者进入一项随机试验，比较单纯放疗与放疗联合环磷酰胺、阿霉素（多柔比星）、甲氨蝶呤和丙卡巴肼的联合化疗。62例接受3周内分15次给予4500拉德放疗的患者中有35例（56.4%）出现客观缓解，49例接受相同放疗和化疗的患者中有19例（38.8%）出现客观缓解。缓解率差异无统计学意义（P = 0.900）。放疗组和联合治疗组的中位进展时间分别为5.9个月和7.02个月。两组患者的中位生存期分别为11.74个月和10.03个月，两组之间无统计学显著差异。毒性是可接受的，两种治疗方案均未发生与治疗相关的死亡。在本研究中，未证明联合放化疗治疗比单纯放疗有显著优势。不同化疗方案在这种情况下是否更有效，应通过进一步研究加以阐明。
